21:22 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Anergis' AllerT meets in Phase IIb for birch pollen allergy

In September, Anergis S.A. (Epalinges, Switzerland) reported top-line data from the Phase IIb ATIBAR trial in 421 patients with birch pollen allergy showing that 50 μg doses of subcutaneous AllerT met the primary endpoint of...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Financial News

Anergis financial update

Anergis S.A. , Epalinges, Switzerland   Business: Inflammation   Date announced: 2016-04-04   Note: Anergis raised CHF5 million ($5.2 million) in an extension of a series B round, bringing the total raised in the round...
00:22 , Jun 3, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Pozen Inc. (NASDAQ:POZN) named Adrian Adams CEO, replacing retiring Chairman, President and CEO John Plachetka. Adams was CEO of Auxilium Pharmaceuticals Inc. , which Endo International plc (NASDAQ:ENDP; TSX:ENL) acquired. Cancer company Ziopharm...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

AllerT: Phase IIb data

Data from 196 patients in the follow-up Phase IIb AN005T trial showed that 50 and 100 ug doses of subcutaneous AllerT each improved mean RSMS scores during the second birch pollen season (2014) following treatment,...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AllerT: Phase II started

Anergis began a double-blind, placebo-controlled, dose-ranging, Canadian Phase II trial to evaluate 10, 25 and 50 µg subcutaneous AllerT given 5 times over 2 months in about 180 patients with birch tree pollen allergy. Anergis...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Financial News

Anergis completes venture financing

Anergis S.A. , Epalinges, Switzerland   Business: Inflammation   Date completed: 2014-12-03   Type: Venture financing   Raised: CHF14.5 million ($14.8 million)   Investors: Sunstone Capital; BioMedInvest; Renaissance PME; WJFS  ...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Pollen for Anergis

By topping off its series B financing, Anergis S.A. hopes to make its short-term birch pollen allergy vaccine into a long-term winner. The additional CHF14.5 million ($15 million) in funding brings the series B total...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

AllerT: Completed clinical trial enrollment

Anergis completed enrollment of 196 patients with moderate to severe birch pollen allergy in a double-blind, placebo-controlled, European observational study evaluating subcutaneous AllerT for up to 3 years. All patients participated in the double-blind, placebo-controlled,...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Financial News

Anergis completes venture financing

Anergis S.A. , Epalinges, Switzerland   Business: Inflammation   Date completed: 2/5/14   Type: Venture financing   Raised: CHF8 million ($8.8 million)   Investors: Sunstone; BioMedInvest; Renaissance PME; Vinci Capital; existing investors; company directors  ...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

AllerT: Additional Phase IIb data

Additional data from the double-blind, European Phase IIb AN004T trial in 240 patients with moderate to severe birch pollen allergy showed that 50 and 100 µg doses of subcutaneous AllerT each led to a 20-fold...